Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...
Vertex Pharmaceuticals Inc.’s nonaddictive drug for lower back pain didn’t do better than a placebo in a midstage trial, ...
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA – Research Report), ...
Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...
Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference ...